Investor Presentation Q1-Q3 2020

62 Investor presentation First nine months of 2020 Biopharm sales growth of 4% driven by solid commercial execution with key brands being NovoSevenⓇ and Norditropin® NovoSevenⓇ and NorditropinⓇ account for 80% of Biopharm sales DKK billion 25 6% 4% -16% -1% 4% Added sales in the haemophilia product portfolio DKK billion 7.7 20 15 10 5 (л 0 2015 2016 2017 2018 Ⓡ NovoSeven Other haemophilia products Ⓡ Norditropin Other biopharm ☐ Growth at CER Note: Company reported sales; CER: Constant exchange rates 4% 7.5 2019 9M 2020 9M 2019 NovoSevenⓇ NovoEight® Other 9M 2020 Novo NordiskⓇ

View entire presentation